Pharma Faces Multiple Challenges in the Year Ahead - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Faces Multiple Challenges in the Year Ahead
Globalization and reform initiatves will shape pharma production, pricing, and pipelines in 2010.


Pharmaceutical Technology
Volume 34, Issue 1, pp. 30-36, 38

Drug quality

Longer supply chains and growing imports raise questions about the ability of drug manufacturers to ensure the quality and safety of all of their drug products. At the same time, FDA cannot feasibly check the thousands of products and ingredients coming into the US. As a result, the agency expects manufacturers to do more to ensure that contractors and suppliers have a commitment to quality and that they are routinely monitored and inspected. The aim is to prevent future adulteration crises such as those involving heparin, melamine, and diethylene glycol (DEG)-contaminated glycerin in medical products.

Along these lines, FDA's Center for Drug Evaluation and Research (CDER) continues to emphasize the importance of manufacturer quality-by-design (QbD) and risk-management systems to ensure drug quality. CDER officials are evaluating a QbD review pilot and launching a similar initiative for biotech therapies. Additional efforts to harmonize quality standards, possibly for excipients and pharmacopeial standards, are under discussion. An electronic drug registration and listing system was fully implemented this past year, replacing paper submissions, which should make it easier for FDA to identify and track products and manufacturing facilities.

Manufacturers also could benefit from a long-awaited FDA guidance on reducing the volume of manufacturing supplements that require preapproval. The aim is to permit companies to report certain changes in annual reports, instead of filing supplements, an approach that will provide more predictability to companies contemplating improvements and scale-up of production processes.

Drug safety and risk assessment

FDA is involved in multiple initiatives to ensure the appropriate use of approved medicines. It will be interesting to see whether the added tools for ensuring drug safety through the product life-cycle encourages agency approval of new medicines that raise safety concerns. The FDA Amendments Act of 2007 (FDAAA) authorizes postapproval label changes when new safety issues arise and penalizes manufacturers that fail to conduct agreed-on postmarketing studies. The Act mandates for a more extensive listing of clinical trials and study results on the ClinicalTrials.gov public website and for the use of Risk Evaluation and Mitigation Strategies (REMS) to govern postmarket prescribing and surveillance.

Manufacturers—along with regulatory authorities, health professionals and patient groups—will be watching to see how well these programs detect and prevent drug safety problems. FDA has approved REMS for more than 90 products, including drugs and medical products already on the market as well as new treatments. A high-profile initiative is to develop a REMS for the entire class of extended-relief opioid medicines. The goal is to ensure continued access to these medications for patients suffering from chronic pain, while also curbing inappropriate prescribing, unintentional overdosing, and intentional abuse through a more coordinated risk- management strategy.

Internally, FDA is bolstering its safety assessment efforts. CDER's Safety First program integrates oversight of drug-safety issues by clarifying responsibility for pre- and postapproval drug safety assessment and by strengthening safety-related policies and procedures. The agency's Sentinel Initiative includes the development of an electronic system for monitoring medical-product safety. After a few pilot projects, the system eventually should be able to identify emerging safety problems and patient subgroups experiencing adverse events through links to healthcare-system databases.

FDA's Safe Use initiative, which Hamburg announced in November, aims to build partnerships with other components of the healthcare system to ensure that medicines are used safely and appropriately. The agency plans to partner with other government agencies and with healthcare providers to address situations that lead to medication errors and inappropriate prescribing.

IT adoption

The Sentinel System for monitoring drug safety requires access to electronic health information systems, a prominent goal of health-reform efforts. The HITECH (health information technology) portion of economic stimulus legislation jumpstarted this effort by providing $19 billion to support the use of electronic health records by doctors and hospitals and to develop standards and systems supporting electronic health information exchange. Electronic databases promise to accelerate detection of drug adverse events and to streamline data collection from clinical trials and population studies.

At the same time, broader access to personal health information has generated demands for stronger protections against unauthorized disclosure of personal patient records. The concern for the biomedical research community is that privacy issues could limit access to patient information needed for pre-clinical and postapproval studies.

An expert panel organized by the Institute of Medicine recommends simplified approaches to clinical research that use a distributed model for health surveillance and assessment, based on the data-sharing capabilities of electronic information systems.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here